ToposarTM - Pfizer
TOPOSAR is contraindicated in patients who have demonstrated a previous hypersensitivity to it. WARNINGS Patients being treated with TOPOSAR must be frequently observed for myelosuppression both during and after therapy. Dose-limiting bone marrow suppression is the most significant toxicity associated with etoposide therapy. ... View Document
HIGHLIGHTS OF PRESCRIBING INFORMATION - Novartis
When given with KISQALI, refer to the Full Prescribing Information for the recommended dose of the aromatase inhibitor being used. When given with KISQALI, the recommended dose of fulvestrant is 500 mg administered on Days 1, 15, 29, and once monthly thereafter. Please refer to the Full Prescribing Information of fulvestrant. ... Return Doc
VOTRIENT (pazopanib) - Caremark
VOTRIENT (pazopanib) recommended in patients with pre-existing hepatic -impairment, defined as total bilirubin > 3 times ULN with any level of ALT. Transaminase and bilirubin levels should beobtained prior to initiation Votrient [package insert]. East Hanover, NJ: Novartis Pharmaceutical ... Content Retrieval
Ramucirumab - Wikipedia
Ramucirumab (LY3009806, IMC-1121B, trade name Cyramza) is a fully human monoclonal antibody (IgG1) developed for the treatment of solid tumors. This drug was developed by ImClone Systems Inc. It was isolated from a native phage display library from Dyax . ... Read Article
RENAL CELL CARCINOMA TREATMENT REGIMENS (Part 1 Of 2)
Pazopanib2,3 Pazopanib 800mg orally once daily without food. Sorafenib 22-25 Sorafenib 400mg orally twice daily without food. Sunitinib 4,26,27 Sunitinib 50mg orally daily with or without food for 4 weeks, followed by 2 weeks off. ... Visit Document
Cobimetinib - Wikipedia
Cobimetinib (trade name Cotellic) is a MEK inhibitor developed by Exelixis and Genentech . It is used in combination with vemurafenib, a BRAF inhibitor, to treat melanoma. ... Read Article
Reference ID: 3122369 - Food And Drug Administration
Debossed on one side. Each tablet contains 216.7 mg of pazopanib hydrochloride equivalent to 200 mg of pazopanib. 4 CONTRAINDICATIONS None. 5 WARNINGS AND PRECAUTIONS 5.1 Hepatic Toxicity and Hepatic Impairment In clinical trials with VOTRIENT, hepatotoxicity, manifested as increases in serum transaminases (ALT, AST) and bilirubin, was observed. ... Get Document
RENAL CELL CARCINOMA CHEMOTHERAPY REGIMENS
Pazopanib (Votrient) 4, 7, 8 Pazopanib 800mg orally once daily. Temsirolimus (Torisel) 9, 10 Temsirolimus 25mg IV once weekly administered over 30–60 min. Sorafenib (Nexavar) 11, 12 Sorafenib 400mg orally twice daily. ... Fetch Doc
HIGHLIGHTS OF PRESCRIBING INFORMATION These Highlights Do Not ...
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use VOTRIENT (safely and effectively. See full prescribing information for VOTRIENT. VOTRIENT® (pazopanib) tablets, for oral use Initial U.S. Approval: 2009 WARNING: HEPATOTOXICITY See full prescribing information for complete boxed warning. ... Read Here
PATIENT INFORMATION A HALAVEN (HAL-ih-ven) HALAVEN (eribulin ...
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use HALAVEN safely and HALAVEN® (eribulin mesylate) injection, for intravenous use See 17 for PATIENT COUNSELING INFORMATION and FDA-approved Patient Labeling ... Access Doc
HIGHLIGHTS OF PRESCRIBING INFORMATION Patients At Risk Of ...
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TARCEVA® safely and effectively. See full prescribing information for ... Get Content Here
HIGHLIGHTS OF PRESCRIBING INFORMATION These Highlights Do Not ...
VOTRIENT (pazopanib) tablets Initial U.S. Approval: 2009 WARNING: HEPATOTOXICITY See full prescribing information for complete boxed warning. Severe and fatal hepatotoxicity has been observed in clinical studies. , reduce, or discontinue dosing as ... Access Content
Votrient® (pazopanib) - Specialtydrug.magellanprovider.com
1. Votrient [package insert]. Research Triangle Park, NC; GlaxoSmithKline; May 2017. Accessed June 2018. 2. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for pazopanib. National Comprehensive Cancer Network, 2018. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL ... Fetch Document
HIGHLIGHTS OF PRESCRIBING INFORMATION Proteinuria: Monitor ...
Refer to everolimus prescribing information for recommended everolimus dosing information. 2.4 Recommended Dosage for Hepatocellular Carcinoma (HCC) The recommended dosage of LENVIMA is based on actual body weight: • 12 mg for patients greater than or equal to 60 kg or • 8 mg for patients less than 60 kg. ... View Full Source
HIGHLIGHTS OF PRESCRIBING INFORMATION With A Fluoropyrimidine ...
3 FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE 1.1 Melanoma KEYTRUDA®(pembrolizumab) is indicated for the treatment of patients with unresectable or metastatic melanoma [see Clinical Studies (14.1)]. 1.2 Non-Small Cell Lung Cancer ... Access Content
Pazopanib STS External Ref List DAC131002
Pazopanib 1. Pazopanib (Votrient) Package Insert –GSK, 10 Dec 2012 2. van der Graff WTA, Blay J-Y and Chawla SP et al. Pazopanib for metastatic soft-tissue ... Fetch Here
RENAL CELL CARCINOMA TREATMENT REGIMENS (Part 1 Of 2)
Pazopanib2,3 Pazopanib 800mg orally once daily without food. Votrient [package insert]. Research Triangle Park, NC: GSK; 2016. 3. Sternberg CN, Davis ID, Mardiak J et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a ... Read More
SPRYCEL (dasatinib) is indicated for the treatment of pediatric patients 1 year of age and older with • Ph+ CML in chronic phase. • newly diagnosed Ph+ ALL in combination with chemotherapy. 2 DOSAGE AND ADMINISTRATION . ... Read Content
HIGHLIGHTS OF PRESCRIBING INFORMATION These Highlights Do Not ...
Tablets containing sorafenib tosylate (274 mg) equivalent to 200 mg of sorafenib. NEXAVAR tablets are round, biconvex, red film-coated tablets, debossed with the “Bayer cross” on one side and “200” on the other side. ... Retrieve Here
HIGHLIGHTS OF PRESCRIBING INFORMATION First-Line Non Squamous ...
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use AVASTIN safely and effectively. See full prescribing information for ... Fetch Content
As Clinically Indicated. Interrupt Iclusig For ANC <1000/mm
HIGHLIGHTS OF PRESCRIBING INFORMATION . These highlights do not include all the information needed to use ICLUSIG safely and effectively. See full prescribing information ... Fetch Document
No comments:
Post a Comment